Skin Lesions Flashcards

0
Q

How are pigmented lesions evaluated?

A

ABCDE: asymmetry, Border irregularity, colors variable, diameter of more than 6 mm, erythema.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Differential diagnosis for skin lesions?

A

Benign lesions – keratoses or pigmented lesions. Malignant lesions – BCC, SCC, adnexal tumors, cutaneous melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name the types of keratoses

A

“SACKS” Seborrheic keratoses, actinic keratoses, cutaneous horns, keratocanthomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe some characteristics of seborrheic keratoses?

A

Common benign lesions, trunks of elderly patients, multiple rounds tan to black well demarcated plaque like, biopsy not necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe general characteristics of actinic keratoses

A

Common, sun exposed areas, 20% progress to squamous cell carcinoma within one year if not treated, raised, red, gritty, scaley

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Treatment for actinic keratoses?

A

Removal by excision, topical 5– fluorouracil, cryotherapy and electrodesiccation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe characteristics of Keratoacanthomas

A

Solitary usually benign, sun exposed skin and adults older than 40, rapidly enlarge over 6–8 weeks, painless firm well circumscribed and raised nodules with shiny unpigmented rim and scaly cratered Center. Should excise.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cutaneous horns

A

Hard scaly conical projections up to several centimeters in length. Most common on face or scalp of elderly, 25% arise from premalignant bases of actinic keratoses and bowens disease, 15% from SCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Bowen’s disease

A

SCC in situ

  • ill-defined, scaly red plaques
  • head and neck
  • biopsy necessary to differentiate from superficial basal cell carcinoma or actinic keratosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Rx for bowen’s disease

A

Treat with superficial removal curettage, electrodesiccation, cryotherapy, shave excision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the four types of nevi?

A

Melanocytic, compound, junctional, architectural disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Melanocytic Nevus

A
  • benign proliferation of melanocytes in the dermis

- no need for excision unless suspicious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Compound melanocytic nevus

A
  • Melanocytes at dermoepidermal junction and dermis

- raised, flesh colored to Brown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Junctional melanocytic nevus

A
  • melanocytes at the dermoepidermal junction
  • m/c in children
  • transforms to compound nevus by adulthood
  • small, flat, brown, regular borders with no distortion of surrounding skin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nevus with architectural disorder

A
  • acquired lesion
  • appeared similar to malignant melanoma, large-size 5 to 10 mm
  • often seen in familial disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Basal Cell Carcinoma

  • incidence?
  • Cause?
  • Where on body?
A
  • m/c skin malignancy, 800,000 cases per year
  • Chronic UV A or B exposure, immunosupppresion
  • sun exposed parts of body
  • pigmented or black
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Types of BCC

A

Superficial BCC
Nodular BCC
Morpheaform or sclerosing BCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Superficial BCC

A

least aggressive
red scaly patch grows to peripheral extension
usually on trunk/extremities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Nodular BCC

A
  • M/C
  • more aggressive
  • pink, elevated, firm and shiny with rolled borders and pearly appearance, usually overlying telangietasia
19
Q

Morpheaform or sclerosing BCC

A
  • more aggressive
  • yellowish or pale plaquelike lesion
  • ill defined borders blend into surrounding skin
20
Q

Treatment for BCC?

A
  • surgical excision with negative histologic margins (2-4 mm normal appearing skin)
  • small well defined lesions with radiation or cryotherapy but rate of recurrence higher and cosmetic results poorer
21
Q

What is the cure rate for BCC?

A

with treatment, >90%

22
Q

Incidence of SCC?

A

2nd m/c skin malignancy

200,000 cases/year

23
Q

Risk factors for SCC

A

sun-exposure, fair skin, hydrocarbons and arsenic, immunosuppression, chronic inflammation

24
Q

Appearance of SCC?

A

Hyperkeratotic, flesh colored, raised, may have ulceration or surrounding erythema

25
Q

Rx for SCC?

A

Surgical excision with negative margins (2-4mm normal appearing skin)

26
Q

What are adnexal tumors?

A

Tumors arising from skin appendages (hair follicles, eccrine, apocrine, and sebaceous glands, fibrous tissue and neural tissue)
-examples: pilomatricoma, merkel cell carcinoma, cylindroma

27
Q

Rx adnexal tumors. Prognosis?

A

Surgical excision, depends on origin of tumor.

28
Q

Incidence of cutaneous melanoma?

A

54,200/year, incidence increased significantly over last 40 years
5th m/c cause cancer in men
7th m/c cause cancer in women

29
Q

Diagnosis of skin lesions?

A
Asymmetry
Border irregularity
Color variation
Diameter > 6mm
Evolution or elevation
30
Q

Types of biopsies?

A

Excisional biopsy preferred. Punch biopsy acceptable for larger.

  • Thickness of tumor most important prognostic indicator, full thickness biopsy.
  • AVOID SHAVE BIOPSY
31
Q

When should sentinel node biopsy be considered?

A

patients without clinical evidence of nodal involvement (palpable nodes) but with reasonable possibility of occult nodal involvement, absence of widely metastatic disease.
-intermediate thickness (1-4mm) most likely to benefit from SNB

32
Q

Is SNB offered for lesions <1mm?

A

if lesion <6% risk of nodal metastasis so SNB not routinely offered. If other risk factors for mets including ulceration, regression, male gender, or axial location.

33
Q

Prognosis for thick melanomas?

A

70% risk of occult systemic mets and 60-70% risk of occult nodal mets.

34
Q

Indications for radical lymphadenectomy?

A

Standard treatment for all patients with REGIONAL NODAL METS (clinically palpable disease proven to be mets by FNA or excisional biopsy of palpable node or SNB+)

35
Q

Indication for adjuvant therapy?

A

interferon alfa-2b improves survival in patients with high risk melanoma (>4mm thickness or nodal mets)

36
Q

What determines risk of recurrence for melanoma?

A

Thickness and +/- nodal mets

37
Q

Where will recurrence of melanoma occur?

A

Wide local excision site and regional nodal basin. Distant mets possible: nods, lung, liver, brain, bone, GIT

38
Q

F/u for patients with thin melanoma?

A

node negative followed q6mo for 2-3 years, then annually 2-3 years

39
Q

F/u for patients with intermediate or thick melanoma?

A

q3-6 months for 3 years, q4-12 months for 2 years, then annually

40
Q

Which factors lead to a poor prognosis and melanoma?

A

Lesions > 0.75mm lesions on the back, arms, neck, and scalp; and female gender

41
Q

Tumor stage Tis

Description and what are the surgical margins?

A

Tumor confined to epidermis.

Surgical margins 5 mm

42
Q

T1 melanoma

Description and surgical margins?

A

Tumor depth < or = 1mm

Surgical margins 1 cm

43
Q

T2 melanoma

Description and surgical margins?

A

Tumor depth of 1.01-2 mm

Surgical margins 1-2 cm

44
Q

T3 melanoma

Description and surgical margins?

A

Tumor depth 2.01 - 4mm

Surgical margins 2 cm

45
Q

T4 melanoma

Description and surgical margins?

A

Tumor depth > 4 mm

Surgical margins > 2 cm